Drugs

Graceful Touch, LLC

FDA issued a warning letter to Graceful Touch, LLC (Rapid City, SD, United States) on Oct 1, 2026, citing 21 CFR 201.128. Subject: Unapproved New Drugs.

From the letter: “No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product.”

Rapid City, SD, United StatesIssued Oct 1, 2026Posted Oct 6, 2026No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
2 findings · 2 issue types
Response due
Fifteen (15) business days of receipt
FDA asks for
4 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Labeling, claims & marketing · 21 CFR 201.128The website marketed Herpes B Gone with claims to treat herpes sores and lower herpes dangers, indicating drug intended use.
On the webpage https://gracefultouchproducts.org/products/herpes-b-gone: - "Herpes B Gone" and images of what appears to be cold sores on the lips. - "Say No to Sores on Your Mouth or Genitals" - "Lower the dangers of herpes virus" - "Herpes B Gone is a certified organic, plant-based cream formulated specifically to soothe herpes sores, calm irritated skin, and support your body's natural healing process — so you can get through an outbreak with less discomfort and more confidence."
02Registration, listing & premarketHerpes B Gone is an unapproved new drug marketed without an FDA-approved application.
No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product. Accordingly, this product is an unapproved new drug.

What FDA requested

  • Provide specific steps taken to correct the violations.
  • Explain each step to prevent recurrence of violations.
  • Submit copies of related documentation.
  • Include any information demonstrating products are not in violation.

FDA Warning Letter

24 paragraphs · 5 sections

Text as published on FDA.gov, retrieved Nov 3, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

DatedOctober 1, 2026
Reference735272
AddressedGuy and Irene Siverson

1Introduction

2 paragraphs

This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://gracefultouchproducts.org/, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.

Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.

2FDA Review

2 paragraphs

Violations were identified and documented during a review of your website https://gracefultouchproducts.org/ in July 2026. Based on our review, “Herpes B Gone” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.

3Violations of the Federal Food, Drug, and Cosmetic Act

1 paragraph

The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.

4Unapproved New Drug Violations

7 paragraphs

Based on a review of your website, “Herpes B Gone” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:

On the webpage https://gracefultouchproducts.org/products/herpes-b-gone:

“Herpes B Gone” and images of what appears to be cold sores on the lips.

“Say No to Sores on Your Mouth or Genitals”

“Lower the dangers of herpes virus”

“Herpes B Gone is a certified organic, plant-based cream formulated specifically to soothe herpes sores, calm irritated skin, and support your body's natural healing process— so you can get through an outbreak with less discomfort and more confidence.”

“Herpes B Gone” is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product. Accordingly, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

5Conclusion

3 paragraphs

As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.

Response requested

Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735272” in the subject line of the email.

Please note FDA posts warning letters on www.fda.gov.

Sincerely,/S/

Tina Smith, M.S.Captain, U.S. Public Health ServiceDirectorOffice of Unapproved Drugs and Labeling ComplianceOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 10, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

Regulations

Issue types

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Rapid City, SD, United States
Letter posted date
Oct 6, 2026
Letter issue date
Oct 1, 2026
Addressed to
Irene Siverson
Inspection dates
Not recorded
Response window
15 business days after receipt of this letter
Read the source clause
Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter.
Record length
818 words · 0 recorded redactions
Published status
No published close-out
FDA reference
735272
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 20, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,711 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.